Absci Corporation Q4 FY2025 earnings call

Sean McClain introduced the call, noting strong fourth quarter with EDS - 201 in clinic, dosing first three SAD cohorts in phase one 2A trial with favorable safety data. Expanded into endometriosis, assembled endometriosis advisory board. Discussed ABS - 201's mechanism in AGA, engineered with extended half - life. Ransi Somaratne detailed ABS - 201 clinical program for AGA and endometriosis, ongoing phase 1 - 2A trial, dosing first three SAD cohorts, favorable safety data. Zach Jonathan discussed strategy, partnerships, financials, revenue $700k, R&D $25.3m, SG&A $8.6m, $5.1m gain, cash position.

Fourth quarter revenue was $700,000. Research and development expenses were $25.3 million for the quarter, primarily driven by advancement of internal programs. Selling, general, and administrative expenses were $8.6 million. A $5.1 million gain on settlement of contingent consideration was recorded.

2026 expected to deliver catalysts: preliminary safety and PK data for ABS201 in first half, interim 13 - week proof of concept regrowth data in second half, initiation of phase two endometriosis trial in Q4 subject to data and regulatory review, full 26 - week proof of concept data for AGA in early 2027.

Risks include material risks and uncertainties in forward - looking statements, clinical development risks such as trial outcomes, regulatory approval, market competition risks affecting commercial prospects.

Q: Question on efficacy and target product profile for ABS - 201, A: Sean and Zach discussed efficacy aiming for at or above minoxidil efficacy with durable treatment and convenient dosing.

Q: Question on safety of ABS - 201, A: Ronzi said early in trial no on - target or off - target safety signal.

Q: Question on partnership discussions, A: Zach said productive discussions with pharma, focused on right deal.

Q: Question on safety profile consistency with non - human primates, A: Ronzi said TEAEs show no mechanism - related safety signal.

Q: Question on molecule engaging target in hair follicles, A: Sean and Ronzi said animal data shows adequate tissue penetration.

Q: Question on comparing anti - PRLR antibody with other agents for AGA, A: Zach and Sean discussed TPP of ABS - 201 resonating with AGA community.

Q: Question on challenges in developing drug for endometriosis, A: Ransi discussed need for careful site selection and placebo mitigation in pain studies.

Q: Question on resource allocation between AGA and endometriosis, A: Zach said both are significant opportunities with streamlined development path.

Q: Question on platform validation relative to other AI - enabled companies, A: Sean and Zach said pharma embraces AI, OriginOne's zero prior epitope design is rigorous.

Q: Question on market opportunity and pricing for AGA and endometriosis, A: Zach said both are large opportunities, pricing to be determined at launch.